On Aug. 31, 2020, a multi-site, Phase 3 clinical trial evaluating an investigational COVID-19 vaccine known as AZD1222 was launched. The trial includes enrollment of approximately 30,000 adult volunteers at 80 sites in the U.S. to evaluate if the candidate vaccine can prevent symptomatic coronavirus disease 2019 (COVID-19).

AstraZeneca is leading the trial as regulatory sponsor. The National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority provided funding support for the trial.